×
You can find our latest news below
We are proud to announce the addition of a new cardiac marker
product — recombinant Growth Differentiation Factor 15 (GDF15) antigen (Cat.
#8DF5).
Japanese Association of Clinical Laboratory Systems (JACLaS) is again around the corner. This year, we are thrilled to announce that our dynamic sales duo, Teppo Heimo and Outi Vilamo, will once again be representing our company at the JACLaS 2025, from 3th to 5th of October.
Get your Flu A/B projects ready for the season. Hytest offers a broad selection of monoclonal antibodies for detecting Influenza A and B. Request your free samples now!
We
are pleased to announce the launch of three new HIV-1 antigen products—8H12,
8H13, and 8H16—that expand our portfolio of solutions for HIV diagnostics. This
launch also reinforces Hytest’s commitment to public health. We remain
dedicated to supporting global efforts in the fight against HIV/AIDS.
While many people now believe that COVID-19 is milder and no longer a threat, it can still pose serious risks. The disease is particularly dangerous for individuals who are immunosuppressed, have chronic medical conditions, or are older.
With new variants continuing to emerge, the virus remains unpredictable. This rapid evolution underscores the importance of tools that can reliably detect not only older strains but also newly emerging ones.
Hepatitis C is an inflammation of the liver caused by hepatitis C virus (HCV). The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious lifelong illness including liver cirrhosis and cancer.
Hytest is excited to introduce a new set of monoclonal anti-Procollagen
Type I N-Propeptide (P1NP) antibodies.
Beta-CrossLaps (β-CTX), also known as beta C-terminal telopeptides, have been designated as reference bone turnover markers (BTMs), together with Procollagen Type I N-terminal propeptide (PINP), in blood by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
Hytest is excited to announce the launch of a new antibody: Recombinant Anti-Human Carcinoembryonic Antigen (CEA) (Cat. # 4CA30cc, MAb: RE16).
Hytest is proud to announce the global launch of its latest innovation: recombinant human Thyroid-Stimulating Hormone (TSH), available under Cat. # 8HTS7.
The article, titled “Design and Analytical Evaluation of Novel Cardiac Troponin Assays Targeting Multiple Forms of the Cardiac Troponin I–Cardiac Troponin T–Troponin C Complex and Fragmentation Forms,” presents a comprehensive analytical evaluation of novel cardiac troponin assays designed by Hytest scientists in collaboration with Dr. Zhenlu Zhang (Wuhan Asia Heart Hospital), Dr. Fred Apple (Hennepin Healthcare/Hennepin County Medical Center), and Dr. Yi Zhang (Mindray Bio-Medical Electronics Co.).
Hytest looks forward to participating in ADLM 2025 (formerly AACC), taking place July 29–31 in Chicago, USA. Come visit us at Booth #1724 to connect with our team and learn how our antibodies and antigens can support your diagnostic solutions.
We are proud to share that Professor Peter Kavsak has been selected as the recipient of the 2025 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics, sponsored by Hytest.
Hytest is excited to announce the launch of its new HIV p24 monoclonal antibodies (MAbs) under Cat. # 3H24. All 7 MAbs--GA12, GA17, GA32, GA34, GA38, GA39, and GA54-- are designed to be used for the development of next-generation HIV p24 antigen immunoassays.
Hytest is excited to announce the launch of its recombinant HCV NS3 antigen (Cat. # 8HC53)—a high-purity reagent developed as capture or detection material for in vitro immunoassays aimed at the qualitative detection of antibodies to Hepatitis C Virus (HCV).
All Hytest SARS-CoV-2 nucleoprotein (NP) antibodies (Cat. #3CV4), including monoclonal antibodies (MAbs) C706, C524, C518, C715, and C527, target the N-terminal part of the nucleoprotein, specifically the region N47-A173.
We are proud to sponsor the EFLM Cardiac Marker Award, which recognizes remarkable scientific work in the field of cardiovascular diseases. This award, presented by the European Federation of Laboratory Medicine (EFLM), honors the best original research paper on cardiac marker measurements and cardiovascular risk assessment.
Hytest is a Leading Raw Material Supplier for the IVD Industry over the past 30 years
We are in the process of developing our North American operations to align with the same standards we use in Hytest Finland.
Copyright © Hytest Ltd.